Whalesbook
Global tensions ka asar
Markets Friday, May 15, 2026 ko thoda cautious open ho sakte hain. US aur China ke beech jo takraar chal rahi hai na, khaas kar Taiwan ko lekar, usse tension aur badh gayi hai. Chinese President Xi Jinping ne bhi warn kiya hai ki cheezein badh sakti hain. Ye sab cheezin market ko affect kar sakti hain, shayad economic data se bhi zyada.
Gift Nifty futures 23,675 ke aas paas chal rahe hain, isse lagta hai Nifty index neeche khul sakta hai.
Company results mein dikhegi alag alag kahani
Global worries ke beech, company results bhi important hain. Aaj Tata Steel, Cochin Shipyard, SAIL, aur Gland Pharma ke Q3 results aa rahe hain. Toh metals, defence, aur pharma sectors pe sabki nazar rahegi.
Ab tak ke results mix hain. Infrastructure aur manufacturing companies bade orders jeet rahi hain, jo achi demand dikhata hai. Lekin kuch pharma players ke profit drop ho rahe hain. Jaise Dr. Reddy's Laboratories ka net profit 86.2% kam ho gaya hai year-on-year. Indian pharma market mein price erosion aur competition hai, lekin growth ho rahi hai.
Defence companies jaise Cochin Shipyard ko government support mil raha hai aur order book bhi badh raha hai. Inki revenue 14% saalana badhne ki ummeed hai.
Investors ka paisa aur market ke pressures
Ek achi baat ye hai ki Foreign Institutional Investors (FIIs) wapas net buyers ban gaye hain, jisne short term support diya hai. Aur Domestic Institutional Investors (DIIs) bhi steady hain. Par market confidence ke liye continuous inflows zaroori hain.
Crude oil prices bhi badh rahi hain, Brent $106.55 aur WTI $102.73 per barrel ke aas paas hain. Isse bhi volatility aa sakti hai.
Aur toh aur, Indian Rupee bhi dollar ke saamne 95.7950 par gir gaya hai, pichle saal 11.91% kamzor hua hai. Rupee ka kamzor hona exporters ke liye faydemand hai, par import cost aur inflation ka risk badh jaata hai.
Analyst kya bol rahe hain aur valuations
Company fundamentals bhi mili-juli hain. Tata Steel ka P/E 29-30 ke aas paas hai aur 'Moderate Buy' consensus hai. Price targets mein mixed outlook dikh raha hai.
SAIL ka consensus 'Strong Buy' hai.
Cochin Shipyard ka P/E kaafi high hai, 59-61, aur analyst consensus 'Sell' hai. Targets mein kaafi downside dikh raha hai.
Gland Pharma, jo pharma exporter hai, uska P/E 36-37 hai aur rating 'Neutral' ya 'Hold' hai. Iski 90% se zyada revenue overseas se aati hai, toh kamzor rupee ka fayda milega.
Kahan kahan risk hai?
Sabse bada risk toh geopolitical tensions hi hain, jo market ko seedha gira sakte hain aur commodity prices mein shock la sakte hain.
Cochin Shipyard bhi risk mein hai uske high valuation aur 'Sell' consensus ke karan. Ye stock earnings se pehle hi kaafi bhaga hai, jo baad mein correction ka sign ho sakta hai. Pichhle 5 saalon mein iski sales growth kam aur return on equity bhi low rahi hai.
Metals sector (Tata Steel, SAIL) economic cycles aur demand par depend karta hai, khaas kar China se. Tata Steel ko earnings miss hone aur global economic pressure ka bhi saamna karna pad sakta hai.
Pharma mein, Gland Pharma ko currency se fayda hai, par sector ko US jaise export markets mein regulatory hurdles aur strong competition ka saamna karna pad raha hai.
Badhti crude oil costs inflation badha sakti hain aur operating expenses bhi badha sakti hain.
Aage ka view kya hai?
Indian pharma sector FY2026 mein 7-9% revenue growth de sakta hai, domestic demand aur kamzor rupee ke karan, US market mein slow growth ke bawajood.
Defence stocks ko government initiatives se structural support mil raha hai.
Individual company outlooks alag hain: SAIL mein strong buy sentiment hai, jabki Cochin Shipyard ko downgrade mil raha hai. Tata Steel ka performance uncertainty navigate karne aur earnings meet karne par depend karta hai, aur Gland Pharma ko exports aur currency se fayda hai.
Market sentiment sudharne ke liye sustained investor inflows aur kam hui geopolitical tensions zaroori hain.